While the therapeutic evidence for meditation and psychedelics has been established as standalone interventions, recent research has started to point potential synergies in combining them. The research team led by Milan Scheidegger conducted a randomized placebo-controlled study aiming to test whether N,N-dimethyltryptamine (DMT), an active ingredient of ayahuasca, and harmine (DMT-harmine) combined with meditation increases (1) mindfulness, (2) compassion, (3) insight, and (4) mystical-type transcendence to a larger degree than meditation with a placebo during a 3-day mindfulness retreat. Findings showed that mindfulness and compassion were not significantly different in the DMT-harmine group compared to placebo. However, the DMT-harmine group self-attributed greater levels of mystical-type experiences, non-dual awareness, and emotional breakthrough during the acute substance effects compared to meditation with a placebo. It seems that DMT-harmine may support meditation and meditation-related well-being through eliciting experiences of insight, transcendence, and meaning rather than through mindfulness or compassion. This study was supported by the BIAL Foundation, in the scope of the research project 333/20 - Mindfulness and psychedelics: A neurophenomenological approach to the characterization of acute and sustained response to DMT in experienced meditators, and published in the Journal of Psychopharmacology, in the article Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat.
ABSTRACT
Background:
In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evidence suggests the promising potential of psychedelics, such as psilocybin, to enhance meditative training, it remains equivocal whether these effects are specifically bound to psilocybin or if other classical psychedelics might show synergistic effects with meditation practice. One particularly promising candidate is N,N-dimethyltryptamine (DMT), an active ingredient of ayahuasca.
Aim:
This study aims to investigate the effect of the psychedelic substance DMT, combined with the monoamine oxidase inhibitor harmine (DMT-harmine), on meditative states, compared to meditation with a placebo.
Method:
Forty experienced meditators (18 females and 22 males) participated in a double-blind, placebo-controlled study over a 3-day meditation retreat, receiving either placebo or DMT-harmine. Participants’ levels of mindfulness, compassion, insight, and transcendence were assessed before, during, and after the meditation group retreat, using psychometric questionnaires.
Results:
Compared to meditation with a placebo, meditators who received DMT and harmine self-attributed greater levels of mystical-type experiences, non-dual awareness, and emotional breakthrough during the acute substance effects and, when corrected for baseline differences, greater psychological insight 1 day later. Mindfulness and compassion were not significantly different in the DMT-harmine group compared to placebo. At 1-month follow-up, the meditators who received DMT and harmine rated their experience as significantly more personally meaningful, spiritually significant, and well-being-enhancing than the meditators who received placebo.
Conclusion:
Investigating the impact of DMT-harmine on meditators in a naturalistic mindfulness group retreat, this placebo-controlled study highlights the specific effects of psychedelics during meditation.
